Printer Friendly

ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS

 ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
 MINNEAPOLIS, June 2 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) announced today that it has signed an agreement with Helixys, Inc. for the production and marketing of HeLa cell nuclear extract and other related products used to study reactions that regulate various cellular processes.
 Investigators use HeLa cell nuclear extracts for the study of cancer, gene expression and viral research. Endotronics will market both bulk material and kits. These products will be targeted primarily to the research market.
 Helixys is a newly incorporated biotechnology consulting firm founded by Dr. Michael Briggs and Benjamin McLemore. Dr. Briggs, chairman of Helixys, said, "This product line provides the research scientist with a rigorously controlled source of HeLa cell extracts. Furthermore, it will free the scientist from the time and cost considerations of maintaining a large tissue culture facility dedicated to growing HeLa cells and the difficulties and variability inherent in preparing their own extracts."
 Richard Sakowicz, president and chief operating officer of Endotronics, said, "Endotronics is uniquely positioned to capitalize on this market opportunity, possessing large-scale cell culture facilities and production expertise. Endotronics and Helixys also plan to collaborate in the development of new products related to research in mammalian cell regulation and expression."
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide.
 -0- 6/2/92
 /CONTACT: Yvonne L. Marschner-Bova of Endotronics, Inc., 313-871-7350/
 (ENDO) CO: Endotronics, Inc.; Helixys, Inc. ST: Minnesota IN: MTC SU: LIC


SB -- DE007 -- 6191 06/02/92 11:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1992
Words:266
Previous Article:NEW MONITOR FUND PURSUES INCOME THROUGH PORTFOLIO OF MORTGAGE-BACKED SECURITIES
Next Article:LEXINGTON EXECUTIVE HEADS NC BANKERS ASSOCIATION
Topics:


Related Articles
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS, INC. RECEIVES U.S. PATENT ON SCALABLE OXYCELL CELL CULTURE TECHNOLOGY
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
ENDOTRONICS, INC. CONFIRMS SCIENTIFIC ADVISORY BOARD FOR BIO-ARTIFICIAL LIVER PROJECT
ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT
ENDOTRONICS, INC. AGREES TO PURCHASE VERAX PRODUCT LINE
CELOX CORPORATION FILES TRADEMARK SUIT AGAINST FORMER ENDOTRONICS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters